ClinicalTrials.gg
CompletedNCT01730534DECLARE-TIMI58Updated Dec 26, 2019Results posted

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

A Phase 3 interventional study of Dapagliflozin 10 mg and Placebo tablet in Diabetes Mellitus, Non-Insulin-Dependent and High Risk for Cardiovascular Event, sponsored by AstraZeneca. Completed at 807 sites in 34 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-12-26.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
17,190
Allocation
Randomized
Ages
40 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
2nd of 180
17,190 · median 82
Started
2013
the only one that year
Phase 3
47 of 180
4 open now
Registered
46th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 47 in phase 3, and was the 46th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 40 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.

03

Conditions studied

  • Diabetes Mellitus, Non-Insulin-Dependent
  • High Risk for Cardiovascular Event

Keywords

  • Phase IIIb
  • T2DM
  • cardiovascular events
04

Who can participate

Ages eligible
40 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study specific procedures
  • Female or male aged ≥40 years
  • Diagnosed with Type 2 Diabetes
  • High Risk for Cardiovascular events

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Type 1 diabetes mellitus History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time
  • Chronic cystitis and/or recurrent urinary tract infections
  • Pregnant or breast-feeding patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17,190 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors

    Drug: Dapagliflozin 10 mg

  • Placebo comparator
    Placebo

    Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors

    Drug: Placebo tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke

    Safety and co-primary efficacy

    Time frame: up to 5.2 years

  2. Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.

    Co-primary efficacy

    Time frame: up to 5.2 years

Secondary outcomes

  1. Subjects Included in the Renal Composite Endpoint: Confirmed Sustained ≥40% Decrease in eGFR to eGFR <60 ml/Min/1.73m2 and/or ESRD and/or Renal or CV Death.

    Secondary

    Time frame: up to 5.2 years

  2. Subjects Included in the Endpoint of All-cause Mortality.

    Secondary

    Time frame: up to 5.2 years

07

Results

Posted Dec 26, 2019

Participant flow

Participant flow — Overall Study
MilestoneDapa 10 mgPlacebo
Started85828578
Completed84738433
Not completed109145
Withdrew: Withdrawal by subject97127
Withdrew: Lost to follow-up1218

Outcome measures

PrimarySubjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke

Safety and co-primary efficacy

Time frame:
up to 5.2 years
Reported as:
Count of participants · Participants
Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke
ParticipantsDapa 10 mgPlacebo
Number of patients with an event756803
Statistical analysis
  • Dapa 10 mg vs Placebo · Regression, Cox · p = 0.172 · Hazard ratio (hr): 0.93 · 95% CI 0.84 to 1.03
PrimarySubjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.

Co-primary efficacy

Time frame:
up to 5.2 years
Reported as:
Count of participants · Participants
Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.
ParticipantsDapa 10 mgPlacebo
Number of patients with an event417496
Statistical analysis
  • Dapa 10 mg vs Placebo · Regression, Cox · p = 0.005 · Hazard ratio (hr): 0.83 · 95% CI 0.73 to 0.95
SecondarySubjects Included in the Renal Composite Endpoint: Confirmed Sustained ≥40% Decrease in eGFR to eGFR <60 ml/Min/1.73m2 and/or ESRD and/or Renal or CV Death.

Secondary

Time frame:
up to 5.2 years
Reported as:
Count of participants · Participants
Subjects Included in the Renal Composite Endpoint: Confirmed Sustained ≥40% Decrease in eGFR to eGFR <60 ml/Min/1.73m2 and/or ESRD and/or Renal or CV Death.
ParticipantsDapa 10 mgPlacebo
Number of patients with an event370480
Statistical analysis
  • Dapa 10 mg vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.76 · 95% CI 0.67 to 0.87
SecondarySubjects Included in the Endpoint of All-cause Mortality.

Secondary

Time frame:
up to 5.2 years
Reported as:
Count of participants · Participants
Subjects Included in the Endpoint of All-cause Mortality.
ParticipantsDapa 10 mgPlacebo
Number of patients with an event529570
Statistical analysis
  • Dapa 10 mg vs Placebo · Regression, Cox · p = 0.198 · Hazard ratio (hr): 0.93 · 95% CI 0.82 to 1.04

Adverse events

Collected over up to 5.2 years. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapa 10 mg529/8,582 (6.2%)3,205/8,574 (37.4%)268/8,574 (3.1%)
Placebo570/8,578 (6.6%)3,418/8,569 (39.9%)342/8,569 (4%)
Most frequent serious events
Showing 10 of 1,643
Most frequent serious events
EventDapa 10 mgPlacebo
Angina unstableCardiac disorders271/8574269/8569
Acute myocardial infarctionCardiac disorders265/8574233/8569
PneumoniaInfections and infestations194/8574219/8569
Cardiac failureCardiac disorders147/8574188/8569
Angina pectorisCardiac disorders154/8574159/8569
Cardiac failure congestiveCardiac disorders121/8574147/8569
Atrial fibrillationCardiac disorders117/8574139/8569
Acute kidney injuryRenal and urinary disorders94/8574127/8569
Myocardial infarctionCardiac disorders96/8574108/8569
Non-cardiac chest painGeneral disorders93/8574107/8569
Most frequent other events
Most frequent other events
EventDapa 10 mgPlacebo
Renal impairmentRenal and urinary disorders121/8574146/8569
Acute kidney injuryRenal and urinary disorders82/8574112/8569
Chronic kidney diseaseRenal and urinary disorders77/8574104/8569

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dapa 10 mgPlaceboTotal
Mean63.9 ± 6.864.0 ± 6.863.9 ± 6.8
Age, Customized
Age, Customized(Participants)Dapa 10 mgPlaceboTotal
<65 years463146229253
>=65 years395139567907
Age, Customized
Age, Customized(Participants)Dapa 10 mgPlaceboTotal
<75 years8044802016064
>=75 years5385581096
Sex: Female, Male
Sex: Female, Male(Participants)Dapa 10 mgPlaceboTotal
Female317132516422
Male5411532710738
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dapa 10 mgPlaceboTotal
Hispanic or Latino129812702568
Not Hispanic or Latino7284730814592
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapa 10 mgPlaceboTotal
White6843681013653
Black or African American295308603
Asian114811552303
American Indian or Alaska Native5252104
Native Hawaiian or other Pacific Islander91322
Other235240475
Baseline CV risk category
Baseline CV risk category(Participants)Dapa 10 mgPlaceboTotal
Established CV disease347435006974
Multiple risk factors for CV events5108507810186
08

Study locations

807 sites
  • Research Site
    Alexander City, Alabama 35010, United States
  • Research Site
    Athens, Alabama 35611, United States
  • Research Site
    Birmingham, Alabama 35243, United States
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Montgomery, Alabama 36106, United States
  • Research Site
    Mesa, Arizona 85206, United States
  • Research Site
    Mesa, Arizona 85213, United States
  • Research Site
    Phoenix, Arizona 85018, United States
  • Research Site
    Alhambra, California 91801, United States
  • Research Site
    Bakersfield, California 93308, United States
  • Research Site
    Greenbrae, California 94904, United States
  • Research Site
    Huntington Park, California 90255, United States
  • Research Site
    La Mesa, California 91942, United States
  • Research Site
    Lomita, California 90717, United States
  • Research Site
    Los Alamitos, California 90720, United States
  • Research Site
    Los Angeles, California 90022, United States
  • Research Site
    Los Angeles, California 90067, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    San Diego, California 92103, United States
  • Research Site
    San Marino, California 91108, United States
  • Research Site
    San Ramon, California 94582, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Ventura, California 93003, United States
  • Research Site
    Vista, California 92083, United States
  • Research Site
    Fort Collins, Colorado 80528, United States
  • Research Site
    Golden, Colorado 80401, United States
  • Research Site
    Bridgeport, Connecticut 06610, United States
  • Research Site
    Bristol, Connecticut 06010, United States
  • Research Site
    Norwalk, Connecticut 06851, United States
  • Research Site
    Stamford, Connecticut 06905, United States
  • Research Site
    Trumbull, Connecticut 06611, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Seaford, Delaware 19973, United States
  • Research Site
    Wilmington, Delaware 19803, United States
  • Research Site
    Washington, District of Columbia 20037, United States
  • Research Site
    Bradenton, Florida 34201, United States
  • Research Site
    Chiefland, Florida 32626, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Coral Springs, Florida 33065, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    Fort Lauderdale, Florida 33308, United States
  • Research Site
    Fort Lauderdale, Florida 33312, United States
  • Research Site
    Green Cove Springs, Florida 32043, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Jacksonville Beach, Florida 32250, United States
  • Research Site
    Jacksonville, Florida 32258, United States
  • Research Site
    Lake Worth, Florida 33461, United States
  • Research Site
    Lakeland, Florida 33805, United States
  • Research Site
    Largo, Florida 33770, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Miami, Florida 33125, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33155, United States
  • Research Site
    Miami, Florida 33175, United States
  • Research Site
    Miami, Florida 33186, United States
  • Research Site
    Naples, Florida 34102, United States
  • Research Site
    New Port Richey, Florida 34653, United States
  • Research Site
    Ocala, Florida 34471, United States
  • Research Site
    Palm Beach Gardens, Florida 33410, United States
  • Research Site
    Pembroke Pines, Florida 33025, United States
  • Research Site
    Pembroke Pines, Florida 33029, United States
  • Research Site
    Pensacola, Florida 32501, United States
  • Research Site
    Saint Petersburg, Florida 33709, United States
  • Research Site
    Saint Petersburg, Florida 33713, United States
  • Research Site
    Spring Hill, Florida 34609, United States
  • Research Site
    Stuart, Florida 34996, United States
  • Research Site
    Tampa, Florida 33634, United States
  • Research Site
    Trinity, Florida 34655, United States
  • Research Site
    Vero Beach, Florida 32960, United States
  • Research Site
    Wellington, Florida 33449, United States
  • Research Site
    Atlanta, Georgia 30308, United States
  • Research Site
    Calhoun, Georgia 30701, United States
  • Research Site
    Cumming, Georgia 30041, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Honolulu, Hawaii 96814, United States
  • Research Site
    Coeur d'Alene, Idaho 83814, United States
  • Research Site
    Arlington Heights, Illinois 60005, United States
  • Research Site
    Chicago, Illinois 60607, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Rock Island, Illinois 61201, United States
  • Research Site
    Anderson, Indiana 46011, United States
  • Research Site
    Avon, Indiana 46123, United States
  • Research Site
    Bloomington, Indiana 47403, United States
  • Research Site
    Evansville, Indiana 47713, United States
  • Research Site
    Evansville, Indiana 47715, United States
  • Research Site
    Evansville, Indiana 47725, United States
  • Research Site
    Greenfield, Indiana 46140, United States
  • Research Site
    Muncie, Indiana 47304, United States
  • Research Site
    Newburgh, Indiana 47630, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Topeka, Kansas 66606, United States
  • Research Site
    Louisville, Kentucky 40205, United States
  • Research Site
    Alexandria, Louisiana 71301, United States
  • Research Site
    Hammond, Louisiana 70403, United States
  • Research Site
    Shreveport, Louisiana 71103, United States
  • Research Site
    Slidell, Louisiana 70458, United States
  • Research Site
    Auburn, Maine 04210, United States

Showing the first 100 of 807 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mosenzon O, Raz I, Wiviott SD, Schechter M, Goodrich EL, Yanuv I, Rozenberg A, Murphy SA, Zelniker TA, Langkilde AM, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Wilding JPH, McGuire DK, Bhatt DL, Leiter LA, Cahn A, Dwyer JP, Heerspink HJL, Sabatine MS. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Diabetes Care. 2022 Oct 1;45(10):2350-2359. doi: 10.2337/dc22-0382. PubMed 35997319 ↗
  • Oyama K, Raz I, Cahn A, Goodrich EL, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2022 Sep 1;7(9):914-923. doi: 10.1001/jamacardio.2022.2006. PubMed 35857296 ↗
  • Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Aylward P, Dalby AJ, Dellborg M, Dimulescu D, Nicolau JC, Oude Ophuis AJM, Cahn A, Mosenzon O, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation. 2022 May 24;145(21):1581-1591. doi: 10.1161/CIRCULATIONAHA.121.058103. Epub 2022 May 5. PubMed 35510542 ↗
  • Cahn A, Wiviott SD, Mosenzon O, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Raz I. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care. 2022 Apr 1;45(4):938-946. doi: 10.2337/dc21-1744. PubMed 35015847 ↗
  • Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Park KS, Goudev A, Diaz R, Spinar J, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur Heart J. 2022 Aug 14;43(31):2958-2967. doi: 10.1093/eurheartj/ehab530. PubMed 34427295 ↗
  • Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021 Aug;44(8):1805-1815. doi: 10.2337/dc21-0076. Epub 2021 Jul 7. PubMed 34233928 ↗
  • Cherney DZI, Dagogo-Jack S, McGuire DK, Cosentino F, Pratley R, Shih WJ, Frederich R, Maldonado M, Liu J, Wang S, Cannon CP; VERTIS CV Investigators. Kidney outcomes using a sustained >/=40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. Clin Cardiol. 2021 Aug;44(8):1139-1143. doi: 10.1002/clc.23665. Epub 2021 Jun 15. PubMed 34129237 ↗
  • Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2021 Jul 1;6(7):801-810. doi: 10.1001/jamacardio.2021.0660. PubMed 33851953 ↗
  • Cahn A, Raz I, Leiter LA, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Wiviott SD. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care. 2021 May;44(5):1159-1167. doi: 10.2337/dc20-2492. Epub 2021 Mar 2. PubMed 33653824 ↗
  • O'Donoghue ML, Kato ET, Mosenzon O, Murphy SA, Cahn A, Herrera M, Tankova T, Smahelova A, Merlini P, Gause-Nilsson I, Langkilde AM, McGuire DK, Wilding JPH, Leiter LA, Bhatt DL, Raz I, Sabatine MS, Wiviott SD. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia. 2021 Jun;64(6):1226-1234. doi: 10.1007/s00125-021-05399-2. Epub 2021 Feb 20. PubMed 33611623 ↗
  • Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, De Mendonca Furtado RH, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MS. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020 Aug 25;142(8):734-747. doi: 10.1161/CIRCULATIONAHA.119.044775. Epub 2020 Aug 3. PubMed 32795086 ↗
  • Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020 Apr 14;141(15):1227-1234. doi: 10.1161/CIRCULATIONAHA.119.044183. Epub 2020 Jan 27. PubMed 31983236 ↗
  • Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes Care. 2020 Feb;43(2):468-475. doi: 10.2337/dc19-1476. Epub 2019 Dec 16. PubMed 31843945 ↗
  • Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MS. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31. PubMed 31474116 ↗
  • Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617. doi: 10.1016/S2213-8587(19)30180-9. Epub 2019 Jun 10. Erratum In: Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20. doi: 10.1016/S2213-8587(19)30221-9. PubMed 31196815 ↗
  • Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019 May 28;139(22):2516-2527. doi: 10.1161/CIRCULATIONAHA.119.039996. Epub 2019 Mar 18. PubMed 30882239 ↗
  • Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18. PubMed 30882238 ↗
  • Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. PubMed 30415602 ↗
  • Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018 Jun;200:83-89. doi: 10.1016/j.ahj.2018.01.012. Epub 2018 Feb 7. PubMed 29898853 ↗
  • Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Am J Manag Care. 2018 Apr;24(8 Suppl):S138-S145. PubMed 29693360 ↗
  • Bloch MJ. Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension. J Am Soc Hypertens. 2016 Mar;10(3):186-7. doi: 10.1016/j.jash.2016.01.001. No abstract available. PubMed 27408945 ↗
  • Leiter LA, Cefalu WT, de Bruin TW, Xu J, Parikh S, Johnsson E, Gause-Nilsson I. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab. 2016 Aug;18(8):766-74. doi: 10.1111/dom.12666. Epub 2016 May 12. PubMed 27009868 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Sep 2018, 64 months.

Results were first posted in Dec 2019, 1 year 3 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 64 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2012
First posted
Nov 21, 2012
StartActual
Apr 25, 2013
Primary completionActual
Sep 11, 2018
CompletionActual
Sep 11, 2018
Results first posted
Dec 26, 2019
Last update
Dec 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01730534
Lead sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb, The TIMI Study Group, Hadassah Medical Organization
Responsible party
Sponsor
First posted
Nov 21, 2012
Start date
Apr 25, 2013
Primary completion
Sep 11, 2018
Completion
Sep 11, 2018
Results posted
Dec 26, 2019
Last update
Dec 26, 2019

Study contacts

Anna Maria Langkilde, MD
study director · AstraZeneca Sweden
Marc S Sabatine, MD, MPH
study chair · TIMI Study Group, Boston, MA, USA
Itamar Raz, MD
principal investigator · Hadassah Medical Organization
Stephen D Wiviott, MD
principal investigator · TIMI Study Group, MA, USA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion